Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
ITGAD Biologics Sequence Review Report 2026: Integrin alpha-D Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ITGAD sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ITGA9 Biologics Sequence Review Report 2026: Integrin alpha-9 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ITGA9 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ITGA7 Biologics Sequence Review Report 2026: Integrin alpha-7 [Cleaved into: Integrin alpha-7 heavy chain; Integrin alpha-7 light chain; Integrin alpha-7 70 kDa form] Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ITGA7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
INHBC Biologics Sequence Review Report 2026: Inhibin beta C chain Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of INHBC sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
GPR179 Biologics Sequence Review Report 2026: Probable G protein-coupled receptor 179 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of GPR179 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
GHRHR Biologics Sequence Review Report 2026: Growth hormone-releasing hormone receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of GHRHR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
FZD8 Biologics Sequence Review Report 2026: Frizzled-8 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of FZD8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
FZD5 Biologics Sequence Review Report 2026: Frizzled-5 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of FZD5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
FZD4 Biologics Sequence Review Report 2026: Frizzled-4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of FZD4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
FZD3 Biologics Sequence Review Report 2026: Frizzled-3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of FZD3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
FCRL6 Biologics Sequence Review Report 2026: Fc receptor-like protein 6 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of FCRL6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
FCRL5 Biologics Sequence Review Report 2026: Fc receptor-like protein 5 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of FCRL5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.